Skip to content

Heart Rate Variability in Benign Paroxysmal Positional Vertigo

Evaluation of Autonomic Function Using Short-Term Heart Rate Variability in Patients With Benign Paroxysmal Positional Vertigo: A Prospective Case-Control Study

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT07472998
Acronym
BPPV-HRV
Enrollment
104
Registered
2026-03-16
Start date
2026-04-01
Completion date
2026-09-01
Last updated
2026-04-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

BPPV, Stress and Anxiety

Keywords

BPPV, stress, HRV, heart rate variability, Benign paroxysmal positional vertigo

Brief summary

Benign paroxysmal positional vertigo (BPPV) is the most common peripheral vestibular disorder. Although the pathophysiology of BPPV is mainly attributed to the displacement of otoconia within the semicircular canals, recent studies suggest that psychological stress and anxiety may be associated with the onset or recurrence of the disease. However, the biological mechanisms underlying this relationship remain poorly understood, and objective evaluation of autonomic nervous system function in patients with BPPV is limited. Heart rate variability (HRV) is a non-invasive method widely used to assess autonomic nervous system activity. Short-term HRV measurements provide information about autonomic balance and vagal tone. In particular, parameters such as the root mean square of successive differences (RMSSD) and the coefficient of variation of RR intervals (COV RR/R) are considered indicators of parasympathetic activity. The aim of this prospective case-control study is to evaluate vagal tone in patients with BPPV using short-term HRV analysis and to compare the findings with age-, sex-, and body mass index-matched healthy controls. Participants will undergo standardized HRV measurements at rest and during controlled breathing. Perceived stress levels will also be assessed using the Perceived Stress Scale (PSS-10). The primary outcomes of the study are RMSSD and the coefficient of variation of RR intervals (COV RR/R), obtained from short-term HRV recordings. These parameters will be compared between BPPV patients and healthy controls, and their associations with perceived stress levels will also be explored. The findings of this study may provide insights into the role of autonomic regulation and stress-related mechanisms in the pathophysiology of BPPV.

Interventions

OTHERShort-term HRV measurement

Short-term heart rate variability (HRV) assessment performed using a non-invasive device that records RR interval variability through hand electrodes. Measurements will be obtained at rest and during controlled breathing to evaluate vagal tone and autonomic nervous system activity.

Sponsors

Istanbul Aydın University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* BPPV Group Age 18 years or older Clinical diagnosis of benign paroxysmal positional vertigo (BPPV) confirmed by positional testing (Dix-Hallpike and/or Roll test) with positional nystagmus No known history of cardiac disease Ability and willingness to provide written informed consent Healthy Control Group Age 18 years or older No history of vertigo or known vestibular disorder Age- and sex-matched to the BPPV group No known history of cardiac disease Ability and willingness to provide written informed consent

Exclusion criteria

* Age younger than 18 years Inability to provide informed consent or impaired mental capacity Known arrhythmia, heart failure, ischemic heart disease, or other clinically significant cardiac disorder Use of medications that may directly affect heart rate variability, including beta-blockers, non-dihydropyridine calcium channel blockers, antiarrhythmic drugs, digoxin, systemic corticosteroids, centrally acting sympatholytic agents, or psychotropic medications that may influence autonomic balance Active infection or systemic inflammatory disease

Design outcomes

Primary

MeasureTime frameDescription
Root Mean Square of Successive Differences (RMSSD)Baseline (At the time of HRV assessment (single visit))Root Mean Square of Successive Differences (RMSSD), expressed in milliseconds (ms), obtained from short-term heart rate variability recordings using the UltraPro S100 EMG/NCS/EP Neurodiagnostic System. RR interval variability will be recorded through hand electrodes during two conditions: resting state and controlled breathing (6 breaths per minute for 60 seconds). RMSSD values will be compared between patients with benign paroxysmal positional vertigo (BPPV) and healthy control participants.
Coefficient of Variation of RR Intervals (COV RR)Baseline (At the time of HRV assessment (single visit))Coefficient of variation of RR intervals (COV RR), expressed as percentage (%), derived from short-term heart rate variability recordings using the UltraPro S100 EMG/NCS/EP Neurodiagnostic System. RR interval variability will be recorded through hand electrodes during resting conditions and controlled breathing (6 breaths per minute for 60 seconds). COV RR values will be compared between patients with benign paroxysmal positional vertigo (BPPV) and healthy controls.

Secondary

MeasureTime frameDescription
Change in RMSSD During Controlled Breathing (ΔRMSSD)Baseline (single HRV assessment visit)Change in Root Mean Square of Successive Differences (ΔRMSSD), expressed in milliseconds (ms), calculated as the difference between RMSSD measured during resting conditions and RMSSD measured during controlled breathing (6 breaths per minute for 60 seconds). This measure reflects vagal reserve and autonomic responsiveness.
Change in COV RR During Controlled Breathing (ΔCOV RR)Baseline (single HRV assessment visit)Change in the coefficient of variation of RR intervals (ΔCOV RR), expressed as percentage points (%), calculated as the difference between COV RR measured during resting conditions and during controlled breathing (6 breaths per minute for 60 seconds).

Countries

Turkey (Türkiye)

Contacts

CONTACTDastan Temirbekov, assistan professor
dasekeeee@gmail.com05314013014

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 17, 2026